Royal Bank of Canada
TARS icon

Royal Bank of Canada’s Tarsus Pharmaceuticals TARS Stock Holding History

Royal Bank of Canada’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208K Sell
2,960
-1,248
-30% -$87.2K ﹤0.01% 4695
2025
Q4 		$344K Buy
4,208
+805
+24% +$60.1K ﹤0.01% 4437
2025
Q3 		$202K Sell
3,403
-186,148
-98% -$9.16M ﹤0.01% 5092
2025
Q2 		$7.68M Buy
189,551
+186,471
+6,054% +$8.39M ﹤0.01% 2233
2025
Q1 		$158K Sell
3,080
-404
-12% -$20K ﹤0.01% 4878
2024
Q4 		$194K Sell
3,484
-3,199
-48% -$145K ﹤0.01% 4842
2024
Q3 		$220K Buy
6,683
+438
+7% +$12.3K ﹤0.01% 4744
2024
Q2 		$170K Buy
6,245
+2,975
+91% +$100K ﹤0.01% 4892
2024
Q1 		$119K Sell
3,270
-9,944
-75% -$292K ﹤0.01% 5086
2023
Q4 		$267K Buy
13,214
+6,931
+110% +$116K ﹤0.01% 4850
2023
Q3 		$111K Buy
6,283
+3,466
+123% +$61.3K ﹤0.01% 5316
2023
Q2 		$50K Buy
2,817
+1,548
+122% +$24.6K ﹤0.01% 5784
2023
Q1 		$16K Sell
1,269
-1,684
-57% -$24.6K ﹤0.01% 6118
2022
Q4 		$43K Buy
2,953
+2,510
+567% +$41.5K ﹤0.01% 5975
2022
Q3 		$8K Buy
443
+121
+38% +$1.92K ﹤0.01% 6550
2022
Q2 		$4K Sell
322
-415
-56% -$6.23K ﹤0.01% 6757
2022
Q1 		$13K Sell
737
-1,410
-66% -$26.2K ﹤0.01% 6841
2021
Q4 		$49K Buy
2,147
+1,222
+132% +$31.8K ﹤0.01% 6387
2021
Q3 		$20K Buy
925
+348
+60% +$8.61K ﹤0.01% 6711
2021
Q2 		$17K Sell
577
-893
-61% -$27.9K ﹤0.01% 6652
2021
Q1 		$48K Buy
1,470
+645
+78% +$23.8K ﹤0.01% 5915
2020
Q4 		$34K Buy
+825
New +$23.5K ﹤0.01% 5822

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada's TARS Position: Q1 2026 in Review

Royal Bank of Canada reduced its Tarsus Pharmaceuticals (TARS) stake by 30% in Q1 2026, selling an estimated $87.2K and leaving 2,960 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #4695.

Royal Bank of Canada first reported a position in TARS in Q4 2020 and has held it in 22 quarters since. The position peaked at $7.68M in Q2 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Royal Bank of Canada held 2,960 shares of Tarsus Pharmaceuticals worth $208K as of Q1 2026.
  • Royal Bank of Canada sold 1,248 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $87.2K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4695 holding.
  • Royal Bank of Canada first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Tarsus Pharmaceuticals position peaked at $7.68M in Q2 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.